Abstract
Decreasing sex hormones levels during the postmenopausal period results in tissue atrophy and physiological changes, such as thinning of the vaginal epithelium, prolapse, and decreased pelvic floor strength and control. Sexual dysfunction associated with vaginal dryness has frequently been reported in postmenopausal women. The present study was designed as an observational, multicenter, real-world clinical investigation to evaluate the performance and safety of the medical device Halova® ovules in reducing vaginal symptoms associated with vulvovaginal atrophy and sexual dysfunction. A total of 249 female participants were treated with Halova® ovules, both in monotherapy and in combination with concomitant medication. The primary objective of this study was to evaluate the tolerability of Halova® ovules in the management of symptoms associated with perimenopause or genitourinary syndrome of menopause. The evolution of clinical manifestations such as vaginal dryness, dysuria, dyspareunia, and endometrial thickness in patients with the aforementioned conditions was defined as a secondary objective. Halova® ovules were rated with “excellent” clinical performance by 92.74% of the study participants as a standalone treatment and 95.71% of the study participants when used in association. Sexual dysfunction-related parameters, such as vaginal dryness and dyspareunia, were reduced by similar percentages in each arm. No adverse reactions related to treatment with Halova® have been reported. Halova® may be a therapeutic alternative for patients with controversial local estrogenic treatment. The study and its details are registered with NCT05654610.
Competing Interest Statement
MDX Research (Ramona Petrita) received a grant support for data management. The decisions on preparation of the manuscript and decision to submit the article for publication remained with the authors. All the other authors declare no competing interests.
Funding Statement
Perfect Care Distribution S.R.L. (https://www.perfectcare.ro/), the study Sponsor, offered the tested medical devices and a partial grant support for data management services. The funder Perfect Care Distribution SRL had no role in the design of the study, or in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Comisia Nationala de Bioetica a Medicamentului si a Dispozitivelor Medicale waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Administrative changes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
